GeneOne Life Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
GeneOne Life Science is a South Korean biotech company focused on developing DNA-based medicines, including therapeutic and preventive treatments for infectious diseases and cancer.
Its products are aimed at patients and healthcare providers, and the company works within the broader pharmaceutical and biotechnology supply chain. Listed on KOSPI, South Korea's main stock exchange, GeneOne is currently in an active research and development phase, with its pipeline of DNA medicines representing the core of its business activity.
Summary is AI-generated and may contain errors · figures from DART filings
GeneOne Life Science in five facts
What does GeneOne Life Science do?
GeneOne Life Science is a South Korean biotech company focused on developing DNA-based medicines, including therapeutic and preventive treatments for infectious diseases and cancer.
Where is GeneOne Life Science listed and in which sector?
GeneOne Life Science (Korean name: 진원생명과학) trades under KRX code 011000 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is GeneOne Life Science?
Its market capitalisation was US$36.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were GeneOne Life Science's latest annual revenue and operating profit?
For fiscal year 2025, GeneOne Life Science reported revenue of US$17.4M, an operating loss of US$33.2M and a net loss of US$39.1M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 35.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Court judgment/ruling on litigationOct 21
- [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of convertible bonds to raise US$11.2M, about 30.9% of its market value.
Capital raise · Oct 15 - [Amended] Shareholder register closure / record date setOct 14
- [Amended] Resolution to convene a general shareholders' meetingOct 14
- [Amended] Other management matter (subsidiary)Oct 12
- [Amended] Other management matter (subsidiary)Oct 8
- Material event report (decision to redeem own convertible bonds early)Capital raise · Oct 7
- [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of convertible bonds to raise US$11.1M, about 30.9% of its market value.
Capital raise · Sep 30 - Other market noticeSep 28
- Other management matter (subsidiary)Sep 23
- Shareholder register closure / record date setSep 18
- Resolution to convene a general shareholders' meetingSep 18
- DisclosureSep 4
- [Amended] Decision to guarantee a third party's debtSep 2
- Other market noticeAug 31
- [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of convertible bonds to raise US$13.8M, about 39.1% of its market value.
Capital raise · Aug 24 - [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of a private placement (third-party allotment) to raise US$10.6M, about 30.9% of its market value.
Capital raise · Aug 10 - Material event report (rights offering)
GeneOne Life Science disclosed a private placement (third-party allotment) to raise US$10.6M, about 30.9% of its market value.
Capital raise · Aug 5 - [Amended] Material event report (decision to sell own convertible bonds)
GeneOne Life Science further amends its April 2026 report on the resale of its own Series 6 convertible bonds to Sunkwang System Co., Ltd., correcting a misstated pre-maturity acquisition figure from US$2.11M to US$1.41M, lowering the sale amount to US$1.06M (136,861 shares at a conversion price of US$7.72, reflecting a 5:1 share-consolidation capital reduction), and pushing back the proceeds receipt date to October 29, 2026.
Capital raise · Jul 30 · 4 versions - Material event report (decision to redeem own convertible bonds early)Capital raise · Jun 18
- [Amended] Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Jun 15 · 4 versions
- [Amended] Decision to acquire shares/equity in another company
GeneOne Life Science updated the disclosed terms of an acquisition, now worth US$1.97M.
M&A · Jun 15 · 4 versions - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · May 7
- [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.43M, about 10.5% of its market value.
Capital raise · Apr 29 - [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.47M, about 10.5% of its market value.
Capital raise · Apr 20 - [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.45M, about 10.5% of its market value.
Capital raise · Apr 17 - [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.45M, about 10.5% of its market value.
Capital raise · Apr 13 - [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.38M, about 10.5% of its market value.
Capital raise · Apr 2 - [Amended] Material event report (convertible bonds)
GeneOne Life Science updated the terms of convertible bonds to raise US$3.41M, about 10.5% of its market value.
Capital raise · Mar 25 - Change of largest shareholderOwnership change · Mar 17
- Material event report (decision to redeem own convertible bonds early)Capital raise · Mar 6
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Mar 4
- [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of a private placement (third-party allotment) to raise US$5.46M, about 16.7% of its market value.
Capital raise · Mar 4 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
GeneOne Life Science reported consolidated results for FY2025: revenue of US$16.5M (−33% year on year), an operating loss of US$29.2M and a net loss of US$32.8M.
Earnings · Mar 3 - [Amended] Supply contract signed
GeneOne Life Science updated a previously disclosed supply contract with TuHURA Biosciences, Inc., now worth US$402K, about 1.43% of its recent annual revenue, running through Feb 2026.
Supply contract · Feb 27 - [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of a private placement (third-party allotment) to raise US$5.62M, about 16.7% of its market value.
Capital raise · Feb 24 - [Amended] Material event report (rights offering)
GeneOne Life Science updated the terms of a private placement (third-party allotment) to raise US$5.54M, about 16.7% of its market value.
Capital raise · Feb 9 - [Amended] Material event report (convertible bonds)Capital raise · Jan 30
- [Amended] Material event report (rights offering)Capital raise · Jan 26